Market Access

Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not achievable?

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

Soaring healthcare costs show little sign of slowing in 2024, with concerns growing about the affordability of medications and medical services.

Although medications such as Mounjaro and Zepbound have shown efficacy in helping individuals lose weight, there are not yet enough results to fully support these claims.

Measuring the relationship between a product’s reimbursement position and performance begins with gathering key data points for as many products as possible.

Starting April 1, 2024, Hyrimoz and an unbranded version of Humira manufactured by Sandoz will be covered across all CVS formularies.

The LillyDirect platform will allow patients who are prescribed the popular weight loss drug Zepbound to obtain the drug via Lilly’s at-home prescription delivery service.

JAMA study investigates whether physical or behavioral healthcare needs are associated with the risk of underinsurance across household income levels.

Five emerging themes likely to impact pharma in the new year.

CVS Health announced a new pharmacy reimbursement model, called CVS CostVantage, which will define drug cost on the amount it pays for a drug, a set markup, and a fee for pharmacy services.

JAMA study evaluates differences in coverage types and potential from 2016-2021.

For manufacturers who participate in the 340B program, costs have increased because they are required to provide steep discounts on their drugs at levels far below private market prices.

JAMA study argues that addressing social determinants of health is crucial to narrowing life expectancy gaps between high- and low-income countries.

Express Scripts has announced plans to offer to a new pharmacy network cost-based pricing option for prescription medications and pharmacy services.

Proposed legislation aims to address pharmacy benefit manager tactics to reduce prescription drug prices.

Novo Nordisk said it will continue providing Levemir vials and the Levemir FlexPen for diabetes control while supplies last, until the full product discontinuation at the end of 2024.

The growing issue of medical debt has caused stakeholders to reevaluate tactics as the cost of pharmaceutical healthcare continues to rise.

Eight rapid-, short-, and long-acting insulin products will move to tier one preferred status, which limits out-of-pocket spending to $35 or less for patients with diabetes.

Inflation Reduction Act expected to reduce maximum achievable revenues for many top selling products.

Inpefa to be added on pharmacy benefit manager’s basic and high-performance formularies for commercially insured patients.

Webinar Date/Time: Tue, Nov 28, 2023 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

Webinar Date/Time: Tue, Nov 14, 2023 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

A look at the intersection of rigorous compliance and ethical behavior: independent, charitable patient assistance foundations.

George Hampton, president and CEO, Currax Pharmaceuticals, discusses the obesity treatment landscape, payment options available to insured and uninsured patients, and how pharma can make obesity treatments more affordable in an exclusive Q&A with Pharm Exec.

Webinar Date/Time: Tuesday, September 19th, 2023 at 8am PDT | 11am EDT | 4pm BST

In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.

In this exclusive Q&A, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, shares her perspective on the biggest drug pricing challenges today, current efforts to lower drug pricing, and the Inflation Reduction Act.

Frederique Welgryn, global vice president for women's health, Perrigo, shares insight into the approval of Opill (norgestrel), a progestin-only contraception, in this exclusive Q&A.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

Webinar Date/Time: Tue, Aug 29, 2023 10:00 AM EDT